文献速递骨质疏松与代谢性骨病

低骨密度代谢组学生物标志物的系统综述

Metabolomic biomarkers of low BMD: a systematic review.
PubMed 文献 · Osteoporos Int · 2021-07-26

部分代谢物组合在区分低BMD与正常方面显示前景,但研究间异质性大,需纵向研究验证。

要点

  • 代谢谱可能改善低BMD的诊断,但证据来自异质性较大的横断面或病例对照研究。
  • 氨基酸类候选代谢物最多,其次为脂质和碳水化合物。
  • 需纵向研究验证代谢谱对低BMD和骨折的预测作用。

核心结论

  • 代谢谱分析可能改善低骨密度的诊断。
  • 现有研究异质性大,需纵向研究验证代谢谱对低BMD和骨折的预测作用。

研究设计与样本

  • 系统综述检索PubMed、Web of Science、Scopus和Embase数据库至2020年4月8日。
  • 纳入采用生物体液标本通过代谢组学平台研究成人低BMD代谢谱的横断面或病例对照观察性研究。

主要发现

  • 部分代谢物组合而非单个代谢物在区分低BMD与正常方面显示前景。
  • 候选代谢物包括氨基酸(最多)、脂质和碳水化合物。
  • 部分研究提示特定代谢通路可能参与。

临床怎么用

  • 代谢谱分析有望作为低BMD诊断的辅助手段,但目前尚不能用于临床常规。
  • 临床解读代谢组学结果时需注意研究间 ethnicity、年龄、样本和平台的异质性。

局限性

  • 纳入研究在参与者种族和年龄、样本及代谢组学平台方面存在很大异质性。
  • 缺乏纵向研究验证代谢谱对低BMD和骨折的预测作用。
  • 未来研究需采用可靠的定量方法以减少异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Due to the metabolic nature of osteoporosis, this study was conducted to identify metabolomic studies investigating the metabolic profile of low bone mineral density (BMD) and osteoporosis. A comprehensive systematic literature search was conducted through PubMed, Web of Science, Scopus, and Embase databases up to April 08, 2020, to identify observational studies with cross-sectional or case-control designs investigating the metabolic profile of low BMD in adults using biofluid specimen via metabolomic platform. The quality assessment panel specified for the "omics"-based diagnostic research (QUADOMICS) tool was used to estimate the methodologic quality of the included studies. Ten untargeted and one targeted approach metabolomic studies investigating biomarkers in different biofluids through mass spectrometry or nuclear magnetic resonance platforms were included in the systematic review. Some metabolite panels, rather than individual metabolites, showed promising results in differentiating low BMD from normal. Candidate metabolites were of different categories including amino acids, followed by lipids and carbohydrates. Besides, certain pathways were suggested by some of the studies to be involved. This systematic review suggested that metabolic profiling could improve the diagnosis of low BMD. Despite valuable findings attained from each of these studies, there was great heterogeneity regarding the ethnicity and age of participants, samples, and the metabolomic platform. Further longitudinal studies are needed to validate the results and confirm the predictive role of metabolic profile on low BMD and fracture. It is also mandatory to address and minimize the heterogeneity in future studies by using reliable quantitative methods. Summary: Due to the metabolic nature of osteoporosis, researchers have considered metabolomic studies recently. This systematic review showed that metabolic profiling including different categories of metabolites could improve the diagnosis of low BMD. However, great heterogeneity was observed and it is mandatory to address and minimize the heterogeneity in future studies.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Panahi N, Arjmand B, Ostovar A, et al. Metabolomic biomarkers of low BMD: a systematic review. Osteoporos Int. 2021. PMID: 34309694. doi:10.1007/s00198-021-06037-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。